We welcome your views on our website and invite you to take part in a brief survey when you've finished your visit.
Your response will help us improve the site and the experience we offer to visitors.
Some of the principal treatments carried out by Dr Emmanuel George at Spire include:
I have a PhD in pharmacology, from Liverpool Medical School. I was awarded this PhD for thesis/work on aspirin and other anti-inflammatory drugs.
I have maintained / consolidated my interests in drugs particularly concentrating on drugs used in management of the inflammatory arthropathies. I have been heavily involved in research/trials as clinical trials co-ordinator for rheumatology unit. I have a special interest and expertise in management and treatment of osteoporosis and intra-articular therapies (injectable treatments for joint diseases).
Osteoporosis; osteoarthritis; inflammatory joint disease eg rheumatoid arthritis etc; crystal arthritis such as gout; connective tissue disorders eg SLE/Lupus etc; pain; soft tissue rheumatism eg tendonitis; back pain inflammatory/non inflammatory.
MB ChB / University of Liverpool / 1984
Bachelor of Medicine
FRCP / London / 1996
Fellow of the Royal College of Physicians
PhD / University of Liverpool / 1979
doctorate in pharmacology
British Society of Rheumatology
Regional Branch of National Osteoporosis Society
National Osteoporosis Society
Member of Drugs and Therapeutics Committee, Arrowe Park Hospital
Chair of regional branch of the National Osteoporosis Society
Honorary Ssenior lecturer, University of Liverpool
Consultant physician and rheumatologist, Wirral Hospitals NHS TrustBack to top
Walking, collecting and reading DC comicsBack to top
|Telephone||0151 929 5181|
|Private secretary||Lesley Snell|
|Private secretary telephone||0151 632 4575|
|Private secretary email||Lesley.Snell@hotmail.co.uk|
11 February 2020
Redbridge-based Spire London East Hospital has been upgraded to a ‘Good’ rating following an inspection by the Care Qual…
04 February 2020
The Paterson Independent Inquiry published its final report on 4 February 2020.